Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against RxSight, Inc. due to allegations of false and misleading statements regarding the company's performance and financial guidance, particularly following a significant drop in stock price after disappointing financial results [2][4][5]. Group 1: Company Performance and Allegations - The complaint against RxSight alleges that the company and its executives violated federal securities laws by failing to disclose "adoption challenges" and structural issues that led to declines in sales and utilization [4]. - RxSight overstated the demand for its products, which resulted in the company being unlikely to meet its previously issued financial guidance for fiscal year 2025 [4]. - Following the release of preliminary second quarter 2025 financial results, RxSight reported significant declines in LDD sales, LAL utilization, and overall revenue, leading to a lowered full year 2025 guidance by approximately $42.5 million at the midpoint [5]. Group 2: Stock Market Reaction - On July 9, 2025, RxSight's stock price fell by $4.84, or 37.8%, closing at $7.95 per share, following the announcement of disappointing financial results and guidance [5]. Group 3: Legal Proceedings - Investors who purchased or acquired securities in RxSight between November 7, 2024, and July 8, 2025, are encouraged to discuss their legal rights and options, with a deadline of September 22, 2025, to seek the role of lead plaintiff in a federal securities class action [2][6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Flywire Corporation securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][5]. Group 1: Class Action Details - Investors who bought Flywire securities between February 28, 2024, and February 25, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by September 23, 2025 [3]. - The lawsuit alleges that Flywire's management made false and misleading statements regarding the sustainability of revenue growth and the impact of permit and visa-related restrictions on the business [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise in this area [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Vestis Corporation during the specified class period of the upcoming lead plaintiff deadline on August 8, 2025, and the potential for compensation without out-of-pocket costs [1][2]. Group 1: Class Action Details - A class action lawsuit has been filed against Vestis Corporation, and investors who wish to serve as lead plaintiffs must act by August 8, 2025 [2]. - The lawsuit alleges that Vestis provided misleading statements about its business growth and strategic initiatives, which ultimately led to investor damages when the truth was revealed [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [3]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [3].

NEW YORK, Aug. 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. ("Alto Neuroscience, Inc." or the "Company") (NYSE: ANRO) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Alto Neuroscience, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired: (a) Alto common stock pursuant and/or ...

Core Points - A class action lawsuit has been filed against Biohaven Ltd. in the U.S. District Court for the District of Connecticut on behalf of investors who acquired Biohaven securities during the period from March 24, 2023, to May 14, 2025 [1][3] - Investors have until September 12, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1][3] Allegations - The lawsuit claims that Biohaven made false or misleading statements regarding the likelihood of regulatory approval for its drug troriluzole to treat SCA, as well as the strength of the supporting data [4] - Additionally, it is alleged that Biohaven overstated the effectiveness and clinical potential of BHV-7000 as a treatment for bipolar disorder [4]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Altimmune, Inc. following a significant decline in its stock price after the announcement of disappointing trial results for Pemvidutide [4][6][7] Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses exceeding $75,000 in Altimmune between August 10, 2023, and June 25, 2025, to discuss their legal rights [1] - A federal securities class action has been filed against Altimmune, with a deadline of October 6, 2025, for investors to seek the role of lead plaintiff [4][8] - The lead plaintiff is defined as the investor with the largest financial interest who directs and oversees the litigation on behalf of the class [8] Group 2: Trial Results and Stock Performance - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial, which failed to achieve statistical significance in its primary endpoint of fibrosis reduction [6] - Following the announcement, Altimmune's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in one day [7]

Core Viewpoint - A securities class action lawsuit has been filed against Altimmune, Inc. for allegedly misleading investors regarding the results of its IMPACT Phase 2b MASH trial, leading to significant stock price decline [1][2][4]. Group 1: Allegations and Trial Results - The lawsuit claims that Altimmune executives provided overly positive statements while concealing adverse facts about the trial results [2]. - The press release announcing the trial results was titled positively, despite one of the primary endpoints not achieving statistical significance [2][3]. - The trial showed a positive trend in fibrosis improvement, but the statistical significance was not met due to a higher-than-expected placebo response [3]. Group 2: Market Reaction - Following the announcement of the trial results, Altimmune's stock price fell from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in one day [4]. Group 3: Legal Proceedings - Investors who purchased shares of Altimmune during the class period are encouraged to contact the law firm representing the class action before the lead plaintiff motion deadline on October 6, 2025 [5].

Core Viewpoint - XPLR Infrastructure, LP is facing a federal securities class action lawsuit due to significant operational changes and alleged misleading statements regarding its business model and financial practices [1][4]. Group 1: Company Actions and Changes - On January 28, 2025, XPLR announced the suspension of cash distributions to common unitholders and a shift from its yieldco model to a new strategy focused on utilizing retained operating cash flows for investments [3]. - The announcement led to a decline in the price of XPLR's common units by $5.31, approximately 33.6%, from $15.80 on January 27, 2025, to $10.49 on January 29, 2025 [3]. Group 2: Allegations in the Lawsuit - The lawsuit claims that XPLR made materially false and/or misleading statements regarding its operational struggles as a yieldco, financing arrangements, and plans to halt cash distributions while redirecting funds to resolve financing issues [4].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Centene To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Centene between December 12, 2024 and June 30, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Aug. 05, 2025 (GLOBE NE ...

Core Points - A shareholder has filed a securities class action lawsuit on behalf of investors who purchased or acquired common stock of Lineage, Inc. in connection with the Company's July 2024 IPO [1][2] - The lawsuit alleges that the defendants made misrepresentations regarding Lineage's business, historical financial results, and industry trends at the time of the IPO [2] Summary by Sections - **Lawsuit Details** - The lawsuit is aimed at investors who bought shares during the IPO and claims misrepresentation by the defendants [1][2] - Investors wishing to serve as lead plaintiff must file by September 30, 2025, and representation is on a contingency fee basis [3] - **Firm Background** - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented large public and private pension funds [4]